Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16080167 | 1.00 | PTPN1 (0.49) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL29384797 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL31714182 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL12052840 | 0.92 | PTPN1 (0.48) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL29349956 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL29047065 | 0.92 | PTPN1 (0.48) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL29358863 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL117946 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL119588 | 0.92 | MDM4 (0.51) | PTPN1MDM4TP53MDM2CTSL | |
| SCHEMBL8100860 | 0.92 | PTPN1 (0.48) | PTPN1MDM4TP53MDM2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153194-A1 | AGENT HAVING ANTI-ICE NUCLEATION ACTIVITY | THE SCHOOL CORPORATION KANSAI UNIVERSITY (JP) | 2018-06-07 | — | — | US | disclosed |
| US-9341629-B2 | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors | PURDUE RESEARCH FOUNDATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9333270-B2 | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors | PURDUE RESEARCH FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9254341-B2 | Methods of manufacture of pteroyl-amino acid-fluorescent dyes | On Target Laboratories, Inc. | 2016-02-09 | — | — | US | disclosed |
| US-20160011199-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | PURDUE RESEARCH FOUNDATION | 2016-01-14 | — | — | US | disclosed |
| US-9233175-B2 | Methods of imaging inflammatory diseases by ligands conjugated to fluorescent compounds | PURDUE RESEARCH FOUNDATION (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233175-B2 | Methods of imaging inflammatory diseases by ligands conjugated to fluorescent compounds | PURDUE RESEARCH FOUNDATION (US) | 2016-01-12 | — | — | US | disclosed |
| US-9061057-B2 | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors | PURDUE RESEARCH FOUNDATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140271484-A1 | Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271484-A1 | Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275533-A1 | Methods of Manufacture and Synthesis of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging of Tumors | On Target Laboratories, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271482-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271476-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | PURDUE RESEARCH FOUNDATION (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140271484-A1 | Methods of Imaging Inflammatory Diseases by Ligands Conjugated to Fluorescent Compounds | FPR3, FPR2, MSR1 | PTPN1 3695/4885MDM4 2650/4885TP53 1397/4885 |
| US-20180153194-A1 | AGENT HAVING ANTI-ICE NUCLEATION ACTIVITY | YBX1, YBX3, TPX2 | PTPN1 209/4885MDM4 647/4885TP53 332/4885 |
| US-20160011199-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | EGFR, TIE1, ERBB2 | PTPN1 4453/4885MDM4 967/4885TP53 25/4885 |
| US-20140271476-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | EGFR, TIE1, ERBB2 | PTPN1 4453/4885MDM4 967/4885TP53 25/4885 |
| US-20140275533-A1 | Methods of Manufacture and Synthesis of Amino Acid Linking Groups Conjugated To Compounds Used For Targeted Imaging of Tumors | MST1R, MET, FOLR1 | PTPN1 4661/4885MDM4 1624/4885TP53 61/4885 |
| US-20140271482-A1 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | EGFR, TIE1, ERBB2 | PTPN1 4453/4885MDM4 967/4885TP53 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.